Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8529667 | 0.89 | LMNA (0.44) | LMNAALDH1A1L3MBTL1KDM4ETDP1 | |
| SCHEMBL2232621 | 0.86 | LMNA (0.53) | LMNAALDH1A1TYMPL3MBTL1KDM4E | |
| SCHEMBL8535158 | 0.85 | KDM4E (0.48) | LMNAALDH1A1TYMPL3MBTL1KDM4E | |
| SCHEMBL1399177 | 0.85 | KDM4E (0.54) | LMNAALDH1A1TYMPL3MBTL1KDM4E | |
| SCHEMBL6983494 | 0.85 | KDM4E (0.54) | LMNAALDH1A1TYMPL3MBTL1KDM4E | |
| SCHEMBL7694338 | 0.85 | KDM4E (0.54) | LMNAALDH1A1TYMPL3MBTL1KDM4E | |
| SCHEMBL3754712 | 0.83 | LMNA (0.50) | LMNAALDH1A1TYMPL3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL7626501 | 0.83 | LMNA (0.50) | LMNAALDH1A1TYMPL3MBTL1KDM4E | |
| SCHEMBL11100222 | 0.80 | LMNA (0.36) | LMNAALDH1A1TYMPTHRB | |
| SCHEMBL8533690 | 0.79 | KDM4E (0.52) | LMNAL3MBTL1KDM4ETDP1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900200-B2 | Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1377583-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| US-5618977-A | Polyiodinated compounds, process of preparation and contrast agent containing them | GUERBET S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| EP-0656884-A1 | NOVEL POLY-IODATED COMPOUNDS, METHOD OF PREPARATION AND CONTRAST PRODUCT CONTAINING SAME | GUERBET S.A. (FR) | 1995-06-14 | — | — | EP | disclosed |
| CN-1090572-A | \" new polyiodide, their preparation method and contain their contrast medium \ | GUERBET SA (FR) | 1994-08-10 | — | — | CN | disclosed |
| WO-1994004488-A1 | NOVEL POLY-IODATED COMPOUNDS, METHOD OF PREPARATION AND CONTRAST PRODUCT CONTAINING SAME | GUERBET S.A. (FR) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | LMNA 4075/4885ALDH1A1 2795/4885TYMP 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.